VAXART INC. DL-,10 revenue breakdown overview

VAXART INC. DL-,10 revenue for the last year amounted to 6.69 M EUR, the most of which — 6.69 M EUR — came from its highest performing source at the moment, Oral Recombinant Protein Vaccines, the year earlier bringing 99.98 k EUR. The greatest contribution to the revenue figure was made by United States — last year it brought VAXART INC. DL-,10 6.69 M EUR, and the year before that — 99.98 k EUR.